{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:51:15Z","timestamp":1791492675378,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvoice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Voice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jvoice.2026.09.029","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:08:41Z","timestamp":1790122121000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Botulinum Toxin B for Laryngeal Dystonia: A Scoping Review"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3862-4404","authenticated-orcid":false,"given":"Brendan Douglas","family":"McNeely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7121-3431","authenticated-orcid":false,"given":"Ying Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1292-1582","authenticated-orcid":false,"given":"Amanda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvoice.2026.09.029_bib1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1288\/00005537-198806000-00012","article-title":"Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases","volume":"98","author":"Blitzer","year":"1988","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.09.029_bib2","first-page":"1","article-title":"Managing botulinum toxin A dosing for laryngeal dystonia","author":"Yuksel","year":"2025","journal-title":"J Voice"},{"key":"10.1016\/j.jvoice.2026.09.029_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/000348949110000201","article-title":"Laryngeal dystonia: a series with botulinum toxin therapy","volume":"100","author":"Blitzer","year":"1991","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jvoice.2026.09.029_bib4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1191\/0269215506cr931oa","article-title":"Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review","volume":"20","author":"Watts","year":"2006","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.jvoice.2026.09.029_bib5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jvoice.2026.09.029_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/mds.20022","article-title":"Clinical presentation and management of antibody-induced failure of botulinum toxin therapy","volume":"19","author":"Dressler","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.jvoice.2026.09.029_bib7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.otohns.2005.09.008","article-title":"Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia","volume":"133","author":"Blitzer","year":"2005","journal-title":"Otolaryngol - Head Neck Surg"},{"key":"10.1016\/j.jvoice.2026.09.029_bib8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/mds.20098","article-title":"Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia","volume":"19","author":"Adler","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.jvoice.2026.09.029_bib9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0892-1997(02)00114-5","article-title":"Botulinum toxin type B for treatment of spasmodic dysphonia: A case report","volume":"16","author":"Sataloff","year":"2002","journal-title":"J Voice"},{"key":"10.1016\/j.jvoice.2026.09.029_bib10","doi-asserted-by":"crossref","unstructured":"Sachdev A, Costello D, Madge S. Botulinum toxin-B injection into the lacrimal gland and posterior cricoarytenoid muscle for the treatment of epiphora and abductor spasmodic dysphonia secondary to Parkinson\u2019s disease. 2019;38:248\u2013251.","DOI":"10.1080\/01676830.2018.1490443"},{"key":"10.1016\/j.jvoice.2026.09.029_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000067023","article-title":"Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis","volume":"49","author":"Dressler","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jvoice.2026.09.029_bib12","first-page":"937","article-title":"Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE Study","volume":"20","author":"Marchetti","year":"2005"},{"key":"10.1016\/j.jvoice.2026.09.029_bib13","doi-asserted-by":"crossref","unstructured":"Stachler R.J., Francis D.O., Schwartz S.R., et al. Clinical Practice Guideline: Hoarseness (Dysphonia) (Update). Vol 158.; 2018. doi:10.1177\/0194599817751030.","DOI":"10.1177\/0194599817751030"},{"key":"10.1016\/j.jvoice.2026.09.029_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.46.1.26","article-title":"Botulinum toxin therapy, immunologic resistance, and problems with available materials","volume":"46","author":"Borodic","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jvoice.2026.09.029_bib15","doi-asserted-by":"crossref","first-page":"NP28","DOI":"10.1093\/asj\/sju027","article-title":"Botulinum toxin type A and B primary resistance","volume":"35","author":"Dobryansky","year":"2015","journal-title":"Aesthetic Surg J"},{"key":"10.1016\/j.jvoice.2026.09.029_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency","volume":"246","author":"Kessler","year":"1999","journal-title":"J Neurol"},{"key":"10.1016\/j.jvoice.2026.09.029_bib17","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jvoice.2026.09.029_bib18","first-page":"e48","article-title":"High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy","volume":"92","author":"P A","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jvoice.2026.09.029_bib19","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s00415-019-09681-7","article-title":"Effective long-term treatment with incobotulinumtoxin (Xeomin\u00ae) without neutralizing antibody induction: a monocentric, cross-sectional study","volume":"267","author":"Hefter","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.jvoice.2026.09.029_bib20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s13555-020-00397-5","article-title":"Association between secondary botulinum toxin a treatment failure in cosmetic indication and anti-complexing protein antibody production","volume":"10","author":"Wanitphakdeedecha","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jvoice.2026.09.029_bib21","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00702-018-1911-3","article-title":"Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity","volume":"125","author":"Dressler","year":"2018","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jvoice.2026.09.029_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000083259","article-title":"Botulinum toxin: mechanism of action","volume":"53","author":"Dressler","year":"2005","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jvoice.2026.09.029_bib23","first-page":"519","article-title":"Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: Rate of onset and radius of diffusion","volume":"29","author":"Flynn","year":"2003","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jvoice.2026.09.029_bib24","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1007\/s00405-024-08688-9","article-title":"Demographic and clinical characteristics of our patients diagnosed with laryngeal dystonia","volume":"281","author":"Asya","year":"2024","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"10.1016\/j.jvoice.2026.09.029_bib25","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1212\/WNL.0000000000011922","article-title":"Laryngeal dystonia: multidisciplinary update on terminology, pathophysiology, and research priorities","volume":"96","author":"Simonyan","year":"2021","journal-title":"Neurology"}],"container-title":["Journal of Voice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199726005059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199726005059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:40:29Z","timestamp":1791492029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0892199726005059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"alternative-id":["S0892199726005059"],"URL":"https:\/\/doi.org\/10.1016\/j.jvoice.2026.09.029","relation":{},"ISSN":["0892-1997"],"issn-type":[{"value":"0892-1997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Botulinum Toxin B for Laryngeal Dystonia: A Scoping Review","name":"articletitle","label":"Article Title"},{"value":"Journal of Voice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvoice.2026.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The Voice Foundation.","name":"copyright","label":"Copyright"}]}}